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MacrophageExperimental autoimmune neuritis (EAN), an autoantigen-speciﬁc T-cell-mediated disease model for human
demyelinating inﬂammatory disease of the peripheral nervous system, is characterized by self-limitation.
Here we investigated the regulation and contribution of erythropoietin (EPO) in EAN self-limitation. In
EAN sciatic nerves, hypoxia, and protein and mRNA levels of hypoxia-inducible factor 1α (HIF-1α), HIF-2α,
EPO and EPO receptor (EPOR) were induced in parallel at disease peak phase but reduced at recovery periods.
Further, the deactivation of HIF reduced EAN-induced EPO/EPOR upregulation in EAN, suggesting the central
contribution of HIF to EPO/EPOR induction. The deactivation of EPOR signalling exacerbated EAN progression,
implying that endogenous EPO contributed to EAN recovery. Exogenous EPO treatment greatly improved
EAN recovery. In addition, EPO was shown to promote Schwann cell survival and myelin production. In
EAN, EPO treatment inhibited lymphocyte proliferation and altered helper T cell differentiation by inducing
increase of Foxp3+/CD4+ regulatory T cells and decrease of IFN-γ+/CD4+ Th1 cells. Furthermore, EPO
inhibited inﬂammatory macrophage activation and promoted its phagocytic activity. In summary, our data
demonstrated that EPO was induced in EAN by HIF and contributed to EAN recovery, and endogenous and
exogenous EPO could effectively suppress EAN by attenuating inﬂammation and exerting direct cell protec-
tion, indicating that EPO contributes to the self-recovery of EAN and could be a potent candidate for treat-
ment of autoimmune neuropathies.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Experimental autoimmuneneuritis (EAN) is a helper T cell-mediated
inﬂammatory demyelinating disease of the peripheral nervous system
(PNS) that mirrors many clinical and immunological features of the
human acute inﬂammatory demyelinating polyradiculoneuropathy
(AIDP), a subtype of Guillain–Barré syndrome (GBS) [1,2]. Patients
with AIDP receive supportive management or active treatments, such
as plasma exchange and intravenous immunoglobulin [3]. While these
treatments are beneﬁcial to some of the patients, only around 65% of
the patients with GBS respond to plasma exchange or intravenous im-
munoglobulin [4]. About 8% of GBS patients die, and up to 20% remain
disabled despite modern treatment. Even in those who recover well, re-
sidual weakness and loss of motor units can usually be detected and
could explain that the fatigue is a common problem [5]. Therefore, ititis; EPO, erythropoietin; EPOR,
HIF, hypoxia inducible factor;
rvous system; LFB, Luxol Fast
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l rights reserved.will be necessary to establish more effective therapeutic strategies for
inﬂammatory polyneuropathies.
Pathologically, EAN is characterized by breakdown of the blood–
nerve barrier, robust accumulation of reactive T cells and macro-
phages and demyelination in the PNS [2]. Further Schwann cells are
the myelinating glial cells of the PNS that support and ensheath
axons with myelin to enable rapid saltatory signal propagation in
the axon. Schwann cells can also modulate local immune responses
by recognizing and presenting antigens and may inﬂuence and termi-
nate nerve inﬂammation by secreting cytokines in EAN [6]. Therefore,
Schwann cells, reactive lymphocytes and macrophages orchestrate a
robust local inﬂammation that is essential for the development and
recovery of EAN.
In contrast to chronic inﬂammatory disorders, EAN is self-limited
with spontaneous recovery, strongly indicating the existence of a reg-
ulatory network capable of suppressing a vigorous autoaggressive im-
mune response. Unravelling mechanisms underlying self-limitation
of EAN may not only deepen our understanding of EAN but also
help the development of new therapeutics.
Erythropoietin (EPO) is produced primarily in the fetal liver and
adult kidney by hypoxia. Low oxygen tension increases activity of
hypoxia-inducible factor (HIF) that binds to cis-acting DNA hypoxia
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quired for the proliferation and differentiation of erythroid progenitor
cells to yield red blood cells through the EPO receptor (EPOR)
expressed on the surface of hematopoietic progenitor cells. In addi-
tion to hematopoietic precursor cells, recently EPOR expression and
biologic response to EPO have been observed in a variety of other
cells, such as Schwann, endothelial, neural, muscle, cardiac, immune,
and other cell types [8–10]. Accumulated recent studies also have
shown that Epo–EpoR signalling contributes to wound healing, angio-
genesis and the body's innate response, indicating that EPO is a po-
tent cyto-protective and anti-inﬂammatory agent [9,11–13]. Given
the known cyto-protective and anti-inﬂammatory functions of EPO
and its induction by hypoxia, which can be induced by inﬂammation,
the contributions of EPO to the self-limitation of EAN are lacking and
worthy of investigation. Therefore, here regulation, effects together
with potential mechanisms of EPO in EAN recovery were studied.
2. Materials and methods
2.1. Animals
Male Lewis rats (8–10 weeks, 200–220 g, Vital River, Beijing,
China) were housed under a 12 h light and 12 h dark cycle with
free access to food and water. All animal procedures were in accor-
dance with a protocol approved by the local Administration District
Ofﬁcial Committee. All efforts were made to minimize the number
of animals and their suffering.
2.2. EAN induction and treatment
EANwas actively induced in Lewis rats. Details of the induction and
evaluation process were described in the Supporting information. For
HIF inhibition, YC-1 (Cayman Chemical Company, Ann Arbor, MI), a
HIF-1α and HIF-2α inhibitor, was given to EAN rats intraperitoneally
at 30 mg/kg/day from Day 12 to Day 13 post immunization (3 rats/
group). Rats in control group received an equal volume injection of
PBS (3 rats/group). To inhibit EPOR functions, EAN rats received intra-
peritoneal (i.p.) injections of erythropoietin mimetic peptide-9
(EMP-9), a proved EPOR antagonist, at 0.5 or 1.0 mg/time, four times
at 1 h intervals/day from Day 12 to Day 19 post immunization (6 rats/
group). The EMP-9 was dissolved in PBS with a ﬁnal concentration of
1 mg/mL and rats in control groups received equal volume injections
of PBS (6 rats/group). For therapeutic treatment, EAN rats received
i.p. injection of recombinant human EPO (rhEPO, 5000 IU/kg, Shenyang
Sunshine Pharmaceutical Company Limited, Shenyang, China) daily
from Day 7 to Day 13 and once every other day from Day 14 to Day
21 (6 rats/group). The EPO was dissolved in PBS and the same volume
of PBS was given to the control group (6 rats/group).
2.3. Immunohistochemistry
To evaluate EPO expression, inﬂammatory cell inﬁltration and path-
ological changes in the PNS, six EPO-treated or control EAN rats were
sacriﬁced at Day 14 or Day 21. Rats were deeply anesthetized with
ether and perfused intracardially with 4 °C, 4% paraformaldehyde in
PBS. Left and right sciatic nerves were quickly removed and post-ﬁxed
in 4% paraformaldehyde overnight at 4 °C. Tissues were cut into two
equally long segments, embedded in parafﬁn, serially sectioned
(3 μm) and mounted on silane-covered slides. The immunostaining
and routine Luxol Fast Blue (LFB) staining together with following
data evaluation were detailed in the Supporting information.
2.4. Tissue preparation and Western blotting
Tissues were homogenized in ice-cold RIPA buffer with 1 mg/mL
of a protease inhibitor cocktail (Beyotime Institute of Biotechnology,Haimen, China). The homogenates were centrifuged at 13,500 rpm for
5 min at 4 °C and the supernatantswere collected. BCA assayswere sub-
sequently performed to determine the protein concentration of the su-
pernatants. Standard protocol was used and following antibodies were
applied: HIF-1α (1:2000 dilution; NB100-479, Novus Biologicals, Little-
ton, CO), HIF-2α (1:2000 dilution; NB100-122, Novus Biologicals, Little-
ton, CO), EPO (1:500 dilution; sc-7956, Santa Cruz, CA), EPOR (1:500
dilution; sc-697, Santa Cruz, CA), GAPDH (1:1000 dilution; AB-P-R
001, Goodhere Biotechnology, Hangzhou, China) and the goat anti-
rabbit IgG-HRP secondary antibody (1:2000 dilution; NBP1-75297,
Novus Biologicals, Littleton, CO). The blots were detected by chemilumi-
nescence with enhanced chemiluminescence reagent (BeyoECL Plus,
Beyotime Institute of Biotechnology, Haimen, China).
2.5. Tissue preparation, RNA isolation, reverse transcription and
real-time PCR
Following treatment, EAN rats were perfused intracardially with
4 °C PBS under anesthesia and then sciatic nerves and inguinal lymph
nodes were quickly removed and stored in liquid nitrogen until RNA
isolation. Total RNA was isolated using Trizol LS Reagent (Invitrogen,
Carlsbad, CA, USA) and reverse transcribed into cDNAusingQuantScript
RT Kit (Tiangen Biotech, Beijing, China). The cDNAwas used tomeasure
the relative expression of genes using RealMasterMix (SYBR green I)
according to the manufacturer's protocol (Tiangen Biotech, Beijing,
China). Real-time measurements of gene expression were performed
with the DNA Engine Opticon 2 Real-Time Cycler PCR detection system
(Bio-Rad Lab., Richmond, CA, USA). Primers used to measure gene
expression were listed in the Supporting information as Table S1.
2.6. Flow cytometric analysis of Foxp3+ regulatory T cells and Th1
cells in spleen
T regulatory cells were identiﬁed as Foxp3+/CD4+ cells and Th1
cells were identiﬁed as IFN-γ+/CD4+ cells. In short, rat spleens were
dissected under sterile conditions and passed through a 40 mm cell
strainer followed by Red Blood Cell Lysis Buffer (BioLegend, San Diego,
USA). For determination of IFN-γ+/CD4+ cells, splenocytes were incu-
bated for 6 h in the presence of 50 ng/mL phorbol-12-myristate-13-
acetate (Sigma, St Louis, MO, USA), 1 mg/mL ionomycin (Sigma, St
Louis, MO, USA) and 1 μg/mL Brefeldin A (Sigma, St Louis, MO, USA)
in ﬂat bottom 96-well plates in RPMI 1640 media (Gibco, Grand Island,
NY) containing penicillin (100 U/mL), streptomycin (100 U/mL) and
10% fetal calf serum at a density of 106 cells/mL at 37 °C and 5% CO2.
Thereafter splenocytes were ﬁxed and permeabilized. AlexaFlour488-
labelled Foxp3 antibody (BioLegend, San Diego, USA) and PE-labelled
CD4 antibody (Tianjin Sungene Biotech Co., Ltd., Tianjin, China) were
used for staining of Foxp3+/CD4+ cells, and PE-labelled IFN-γ antibody
and FITC-labelled CD4 antibodywere used for staining of IFN-γ+/CD4+
cells according to the standard protocol. For all staining, isotype controls
were used. Following staining, cellswerewashed and suspended in PBS,
and then analyzed by a FACScan (BD Biosciences, Franklin Lakes, NJ,
USA). Mononuclear cells were gated by forward scatter and sideward
scatter.
2.7. Cell culture and treatment
Rat RSC96 Schwann cells, murine RAW 264.7 macrophages and
Jurkat cells were grown in complete DMEMmedia (Gibco, Grand Island,
NY) containing penicillin (100 U/mL), streptomycin (100 U/mL) and
10% FCS at 37 °C and 5% CO2.
For RSC96 Schwann cells, rhEPO effects on cell proliferation, apo-
ptosis, LPS-induced inﬂammatory activation and EPOR induction
were studied, and detailed methods were described in the Supporting
information.
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matory activation, phagocytosis and EPOR induction were detected,
which was detailed in the Supporting information.
For Jurkat cells, rhEPO effects on cell proliferation and EPOR induc-
tion were measured, and corresponding methods were detailed in the
Supporting information.2.8. Data evaluation and statistical analysis
The unpaired t-test or Mann–Whitney U test was performed to
compare difference between EPO and control EAN rats (GraphPadFig. 1. EPO and EPOR were induced by HIF in sciatic nerves of EAN rats. A: Representative W
21 EAN rats (n = 3). Rats were sacriﬁced 1 h after injection of pimonidazole to detect the
ducts, and HIF-1α, HIF-2α, EPO and EPOR were signiﬁcantly enhanced at Day 14 and retu
in sciatic nerves of naive and EAN rats. The mRNA expression of HIF-1α, HIF-2α, EPO and E
21. C: YC-1 was i.p. injected (30 mg/kg/day) into EAN rats from Day 12 to 13 post immuniza
of HIF-1α, HIF-2α, EPO and EPOR in the sciatic nerves was quantiﬁed by Western blotting. T
ment in comparison to vehicle control.Prism 5.0 for windows). For all statistical analyses, signiﬁcance levels
were set at P b 0.05.
3. Results
3.1. EPO/EPOR was induced by HIF in sciatic nerves of EAN rats
In our study, the ﬁrst neurologic sign of EAN rats was observed
around Day 9, the neurologic severity of EAN reached maximum
around Day 14 and disappeared around Day 21 (data not shown).
Here we ﬁrst examined the oxygenation states using pimonidazole
hydrochloride, a hypoxic marker, and levels of HIF-1α and HIF-2α,estern blot analysis and semi-quantiﬁcations of sciatic nerves of naive, Day 14 and Day
protein adducts of reductively-activated pimonidazole. The protein pimonidazole ad-
rned to normal levels by Day 21. B: RT-PCR analysis of HIF-1α/HIF-2α and EPO/EPOR
POR was signiﬁcantly induced at Day 14 and returned to normal control levels at Day
tion (3 rats/group). The rats were sacriﬁced 12 h after the last injection and expression
he protein levels of HIF-1α/HIF-2α and EPO/EPOR were greatly reduced by YC-1 treat-
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tors, in sciatic nerves of EAN rats. For detection of oxygenation state,
EAN rats were sacriﬁced 1 h after injection of pimonidazole and the
protein adducts of reductively-activated pimonidazole were detected
by Western blotting with Hypoxiprobe-1-Mab-1 (Hypoxyprobe kit;
Chemicon International) following the manufacturer's instructions.
As shown in Fig. 1A, the protein pimonidazole adduct levels were
signiﬁcantly increased on Day 14, the peak of EAN neurological dis-
ease severity, and returned to normal control level on Day 21, the re-
covery phase of EAN, compared to normal control. Therefore, the
oxygenation state was in parallel with EAN disease severity, indicat-
ing the existence of inﬂammation induced hypoxia in inﬂamed nerves
of EAN rats. Similarly, the protein and mRNA levels of HIF-1α and
HIF-2α were signiﬁcantly induced on Day 14 and returned to normal
control level on Day 21 (Figs. 1A,B and S1).
Interestingly, in parallel with the induction of HIF, the protein and
mRNA levels of EPO and EPOR were induced in sciatic nerves of EAN
rats, implying that HIFmight play a role in regulating EPR/EPOR expres-
sion (Fig. 1A,B). To verify the contribution of HIF in EPR/EPOR induction,
YC-1, a HIF-1α and HIF-2α inhibitor, was given to EAN rats fromDay 12
to 13 post immunization to inhibit the activity of HIF [14]. Rats were
sacriﬁced 12 h after the last injection, and thereafter the expression of
HIF-1α, HIF-2α, EPO and EPORwasmeasured byWestern blot in sciatic
nerves. As shown in Fig. 1C, the protein level of HIF-1α and HIF-2αwas
greatly reduced byYC-1 compared to vehicle control (P b 0.05), indicat-
ing the effectiveness of YC-1. Accordingly, the protein level of EPO and
EPOR was signiﬁcantly decreased as well (P b 0.05), suggesting an es-
sential role of HIF in regulating EPO/EPOR expression in EAN.
As EPOR hasn't been identiﬁed as a direct target gene regulated by
HIF we further analyzed the effects of EPO on EPOR expression in
EAN. EPO or PBS was given to EAN rats from Day 7 to 14. 24 h after
the last injection, sciatic nerves were taken for EPOR expressionFig. 2. Blockade of endogenous EPO exacerbated the progression of EAN. EMP-9 was i.p. injec
immunization (6 rats/group) and the progression of EAN was evaluated. A: EMP-9 treatmen
and extending EAN duration. B: Sciatic nerves from control and EMP-9-treated EAN (Day
increased, while TGF-β level was decreased. C: LFB staining was applied to show myelin
that the incidence of perivascular demyelination and inﬂammatory cell inﬁltration was signanalysis. As shown in Fig. S2, EPO treatment greatly upregulated
EPOR mRNA level. Furthermore, EPO also dose-dependently in-
creased mRNA levels of EPOR in Schwann cells, macrophages and T
cells in vitro (Fig. S2). Therefore, the induced EPOR upregulation in
EAN could be owing to the HIF-induced EPO.
3.2. Endogenous EPOR signalling contributed to the self-recovery of EAN
While EPO and EPOR were induced in EAN their role in EAN
self-limitation is unclear. To deprive EPOR signalling in EAN, a proved
EPOR antagonist, EMP-9, was used [15]. As shown in Fig. 2A, EMP-9
treatment dose-dependently exacerbated EAN by increasing neuro-
logic severity, delaying EAN recovery and extending EAN duration.
Further EMP-9 treatment signiﬁcantly increased IFN-γ, TNF-α and
IL-17 levels and decreased TGF-β expression in sciatic nerves of Day
20 EAN rats (Fig. 2B). In addition, the incidence of perivascular demy-
elination and inﬂammatory cell inﬁltration in Day 20 EAN sciatic
nerves was signiﬁcantly increased by EMP-9 treatment (Fig. 2C).
Therefore, our data indicate that endogenous EPOR signalling contrib-
uted to the recovery of EAN.
3.3. Exogenous EPO treatment favored the alleviation of EAN
We further studied the therapeutic effects of exogenous EPO on
EAN. rhEPO or PBS (control group) was injected into EAN rats from
Day 7 to 21. Treatment with rhEPO greatly decreased neurologic sever-
ity and shortened recovery time and total duration of EAN (Fig. 3A).
Furthermore, weight loss in EAN rats was signiﬁcantly improved by
rhEPO as well (Fig. 3A). In addition, rhEPO treatment signiﬁcantly de-
creased the incidence of perivascular demyelination and inﬂammatory
cell inﬁltration in sciatic nerves of EAN rats (Fig. 3B).ted (0.5 mg/time, four times at 1 h intervals/day) into EAN rats from Day 12 to 19 post
t exacerbated EAN by increasing neurologic severity of disease, delaying EAN recovery
20) rats were taken for RT-PCR analysis. mRNA levels of IFN-γ TNF-α, and IL-17 were
of Day 20 control- and EMP-9-treated EAN rats. Representative microimages showed
iﬁcantly increased by EMP-9 treatment (n = 3).
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cytokines in sciatic nerves of EPO-treated EAN rats. For Day 14 EAN
rats, while EPO reduced IFN-γ, TNF-α, IL-1β and IL-17 levels and in-
creased the IL-4, TGF-β and IL-10 levels, signiﬁcant differences wereFig. 3. EPO treatment attenuated EAN disease severity, suppressed demyelination and altere
rats from Day 7 to Day 21. All rats were monitored daily for body weight and neurological
nerves for LFB staining or RT-PCR analysis. A: EPO treatment greatly decreased neurologic se
the PBS-treated group. B: LFB staining was applied to showmyelin of Day 14 in EAN sciatic ne
signiﬁcantly suppressed by EPO treatment in comparison to the PBS control group (n = 3). C
analysis. IFN-γ, TNF-α, IL-1β, and IL-17 levels were reduced, while IL-4, TGF-β, and IL-10 leonly observed for TNF-α, IL-17, IL-4 and TGF-β (Fig. 3C). However,
for Day 21 EAN rats, EPO treatment greatly decreased IFN-γ, TNF-α,
IL-1β and IL-17 levels and increased the IL-4 TGF-β and IL-10 levels
(Fig. 3D).d cytokine expression in sciatic nerves. PBS or rhEPO was therapeutically given to EAN
signs of EAN, and on Day 14 or Day 21, the rats (n = 6) were sacriﬁced to take sciatic
verity of EAN, shortened EAN duration and reduced body weight loss in comparison to
rves. Representative microimages showed that demyelination and cell inﬁltration were
–D: Sciatic nerves from Day 14 and Day 21 EPO-treated EAN rats were taken for RT-PCR
vels were increased.
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Schwann cells
Since both endogenous and exogenous EPO were shown to alter
demyelination/remyelination in EAN, effects of EPO on rat Schwann
RSC96 cells were further analyzed. As shown in Fig. 4A, RSC96 cell apo-
ptosis induced by hydroxyperoxide was dose-dependently reduced by
rhEPO. rhEPO also dose-dependently promoted RSC96 cell proliferationFig. 4. EPO exerted direct cyto-protective and anti-inﬂammatory effects on Schwann cells.
RSC96. A: Schwann cell apoptosis was induced by 5 h stimulation with 100 μM H2O2, and ap
is shown (n = 3). The apoptosis rate of H2O2-injured RSC96 cells was reduced by 20 IU/m
levels of P0, MBP, and Krox-20 by RT-PCR were signiﬁcantly increased by EPO. C: RSC96 cel
of TNF-α and iNOS were signiﬁcantly reduced by EPO.(Fig. S3A). Interestingly, we also found that rhEPO increased mRNA ex-
pression of Krox-20, the transcription factor regulating myelination in
Schwann cell, and myelin associated protein P0 and myelin basic pro-
tein in RSC96 cell with a dose-dependent manner (Fig. 4B). In addition,
AG490, a tyrosine kinase inhibitor that inhibits JAK2, dose-dependently
cancelled the effect of rhEPO on myelin formation, suggesting that the
myelin induction function of EPO in Schwann cells was through the ac-
tivation of JAK2 (Fig. S3B).Effects of EPO on Schwann cells were analyzed in vitro using the rat Schwann cell line
optosis rate was quantiﬁed by ﬂow cytometry. Representative ﬂow cytometry dot plot
L and 40 IU/mL EPO. B: Cells were treated with different doses of EPO for 24 h. mRNA
ls were stimulated with LPS for 4 h and then incubated with EPO for 8 h. mRNA levels
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vation were analyzed as well [6]. Following LPS stimulation, the
mRNA levels of TNF-α and iNOS in RSC96 cells were greatly induced,Fig. 5. EPO suppressed lymphocyte proliferation and altered Th cell differentiation in EAN. P
tative microimages of immunohistochemical staining of CD3+ T cells in EAN sciatic nerves o
pared to the PBS control group. B: The percentage of CD4+ Th cells in EAN spleen on Day 14
cell numbers in EAN spleen on Day 14 and Day 21. EPO treated EAN. C: In the lymphocyte p
after a total of 72 h culture, the speciﬁc cell proliferation of splenocytes by P2 peptide was s
icantly decreased mRNA levels of T-bet, IL-12p35, RORγt, and IL-6, but increased GATA3, I
showed that in Day 14 EAN spleen, IFN-γ+CD4+ Th1 cell numbers were decreased in th
(n = 3).indicating an inﬂammatory activation (Figs. 4C and S3C). However,
following co-incubation with rhEPO, the up-regulated TNF-α, iNOS
and NO were dose-dependently reduced (Figs. 4C and S3C).BS or rhEPO was therapeutically given to EAN rats from Day 7 to Day 21. A: Represen-
n Day 14 (n = 3). The accumulation of CD3+ T cells was greatly reduced by EPO com-
and Day 21 was determined by ﬂow cytometric analysis. EPO greatly reduced CD4+ Th
roliferation assay, spleen mononuclear cells were stimulated by P2 antigen peptide and
igniﬁcantly inhibited by EPO. D: In EAN lymph nodes on Day 14, EPO treatment signif-
L-4, and Foxp3 compared to the PBS group. E: Representative ﬂow cytometry dot plot
e EPO-treated group, while Foxp3+CD4+ regulatory T cell numbers were increased
1267B. Luo et al. / Biochimica et Biophysica Acta 1832 (2013) 1260–12703.5. EPO suppressed lymphocyte proliferation and altered T helper cell
differentiation in EAN
One of the most important immune cells in EAN is the T lympho-
cyte. The proliferation and polarization of T lymphocytes following
auto-antigen stimulation is a central process deﬁning the nature and
severity of autoimmune disorders. The draining lymph node is theFig. 6. EPO promoted sciatic nerve macrophage accumulation in EAN and inhibited inﬂamm
rats from Day 7 to Day 21. Sciatic nerves were taken from Day 14 and Day 21 EAN rats for ED-
showed that macrophage accumulation in sciatic nerves of EAN rats was signiﬁcantly reduc
were treated with 1 μg/mL LPS followed by rhEPO or PBS control treatment with various do
reduced by rhEPO treatment. C: 0.5 mg/mL FITC-dextran was incubated with RAW264.7 cel
of FITC-dextran by RAW264.7 cell was greatly up-regulated in the presence of EPO. ⁎: P b 0most important place for T cell activation, differentiation and prolifer-
ation. Therefore, we ﬁrst investigated the EPO/EPOR expression in in-
guinal lymph nodes in EAN. As shown in Fig. S4, mRNA levels of EPO
and EPOR were signiﬁcantly induced on Day 14 and returned to nor-
mal control level on Day 21 in EAN inguinal lymph nodes, indicating
the potential participation of EPO in regulating T lymphocyte func-
tions (Fig. S4). Furthermore, in EAN rats, the percentage of helperatory macrophage activation in vitro. A: PBS or rhEPO was therapeutically given to EAN
1 immunostaining. Representative microphotos together with semi-quantiﬁed analysis
ed on Day 14 and increased on Day 21 following rhEPO treatment. B: RAW 264.7 cells
ses for 4 h or 8 h. mRNA levels of TNF-α and iNOS, and NO concentrations were greatly
ls for 30 min at 37 °C and phagocytosis was measured by ﬂow cytometry. Phagocytosis
.05 and ⁎⁎: P b 0.01 compared to their respective vehicle control.
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(CD3+ cells) in sciatic nerves were greatly reduced following rhEPO
treatment (Fig. 5A,B). EPO dose-dependently suppressed antigen
speciﬁc- and antigen non-speciﬁc-lymphocyte proliferation in vitro
(Figs. 5C and S5). Therefore, represented data here indicated that the
induced EPO/EPOR in draining lymph nodes may inhibit lymphocyte
proliferation to reduce the inﬁltration of activated T lymphocyte to
PNS to contribute to EAN recovery.
In addition,we found that, for Day 14 EAN rats, rhEPO treatment sig-
niﬁcantly reduced the mRNA level of T-bet, master transcription factor
for Th1 cells, and RORγt, master transcription factor for Th17 cells, but
greatly increased levels of the GATA3, master transcription factor for
Th2 cells, and Foxp3, master transcription factor for regulatory T cells,
in inguinal lymph nodes. Correspondingly, cytokine IL-12p35 and IL-6,
which favor Th1 and Th17 differentiation, were reduced but cytokine
IL-4, implying Th2 differentiation,was induced (Fig. 5C).We further an-
alyzed percentages of Th1 and regulatory T cells in the spleen at Day 14
EAN rats that were therapeutically treated by rhEPO. rhEPO treatment
signiﬁcantly reduced the CD4+/IFN-γ+ Th1 cells but increased the
CD4+/Foxp3+ regulatory T cells compared to the PBS control (Fig. 5D).
3.6. EPO promoted sciatic nerve macrophage accumulation in EAN and
inhibited inﬂammatory macrophage activation in vitro
In EAN PNS, macrophages have critical functions in promoting in-
ﬂammation, terminating the immune reaction and promoting periph-
eral nerve recovery following the autoimmune insult [16]. Here we
also investigated effects of EPO on macrophages.
In sciatic nerves of EAN rats, while macrophage accumulation was
signiﬁcantly reduced on Day 14 (at the peak of disease severity) its ac-
cumulation was greatly increased on Day 21 (in the remission phase)
following rhEPO treatment (Fig. 6A). Furthermore, in vitro experiments
showed that EPOdose-dependently suppressed LPS-induced inﬂamma-
tory activation of RAW264.7 macrophage by reducing TNF-α, iNOS and
NO levels (Fig. 6B). Interestingly, our results here also showed that EPO
greatly increased the phagocytic capacity of macrophages, which is es-
sential to remove apoptotic cells and debris to promote EAN remission,
in a dose-dependent way in vitro (Fig. 6C).
4. Discussion
While themechanisms andmediators that regulate the onset of EAN
have beenwell characterized, relatively little is knownabout the endog-
enous mechanisms that promote EAN recovery. In the EAN model, we
observed that hypoxia paralleled the expression of HIF and EPO/EPOR
in sciatic nerves during peak and recovery periods. The deactivation of
HIF reduced EAN-induced EPO/EPOR upregulation, suggesting a central
contribution of HIF to EPO/EPOR induction. Furthermore, the deactiva-
tion of EPOR exacerbated EAN progression, implying that endogenous
EPO contributed to EAN recovery. Further, therapeutic treatment with
rhEPO greatly suppressed paraparesis in EAN. In addition, EPO exerted
direct cyto-protective and anti-inﬂammatory effects on Schwann cells,
T cells and macrophages, which are the three major cells regulating
EAN progression and recovery. Therefore, our data identiﬁed EPO as a
HIF-induced endogenous protective molecule contributing to the self-
limitation of EAN.
Accumulated data have established that sites of acute inﬂammation
are characterized by shifts in the supply and demandofmetabolites that
result in limited oxygen availability (inﬂammation-associated hypoxia)
[17,18]. In our investigation, hypoxiawas closely in linewith the disease
severity of EAN, which mirrors the inﬂammation severity in peripheral
nerves. In agreement with hypoxia, HIF-α protein was induced in EAN.
Under normoxic conditions, the HIF-α subunits are unstable owing to
the activity of a family of oxygen-dependent prolyl hydroxylases, the
activation of which directs HIF-α subunits for degradation [19,20].
Therefore, the level of HIF-α in sciatic nerves of EAN reﬂected thehypoxic states in peripheral nerves. Furthermore, our present study re-
vealed that the mRNA level of HIF-α (HIF-1α and HIF-2α) in sciatic
nerves of EAN rats was induced as well. While the protein stability of
HIF-α is inﬂuenced by the oxygenation states, the transcription of
HIF-α is known to be induced by several inﬂammatory mediators,
such as TNF-α, NO and IL-1β [21,22]. In peripheral nerves of EAN rats,
the increase of TNF-α, NO and IL-1β is well documented [23],
which may explain the increased mRNA levels of HIF-α. Therefore,
the increased HIF-α in EAN could be due to both hypoxia-dependent
and -independent pathways.
Furthermore, our data showed that EPO and EPORexpression in EAN
was in parallel with the HIF-α (HIF-1α and HIF-2α) level and,more im-
portantly, the deactivation of HIF suppressed EPO and EPOR expression,
implying the important contribution of HIF to EPO and EPOR induction
in EAN. The HIF complex consists of an oxygen labile α-subunit
(HIF-1α, -2α, and -3α) and a constitutive β-subunit [24]. While
HIF-3α encodes a polypeptide that antagonizes HRE-dependent gene
expression, HIF-1α and HIF-2α are closely related, and both activate
HRE-dependent gene transcription [17,25,26]. EPO and EPOR are single
gene products. It is well established that the expression of EPO is medi-
ated by HIF transcription in response to hypoxia [27]. Although HIF-1α
was initially thought to control EPO gene expression, recent studies in-
dicate a dominant role for HIF-2α in regulating EPO synthesis in vivo
[28,29]. In EAN, both HIF-1α and HIF-2α were induced, but which HIF
complex contributed to the upregulated EPO in EAN is not clear and
needs further investigation.
Compared to EPO, relatively little is known about regulation of
EPOR expression [30]. Similar to our observations, in solid tumors
and brain injury, both EPO and EPOR are expressed in hypoxic areas,
leading to the speculation that EPOR expression may be enhanced by
hypoxia as well [31,32]. However, HIF-1α and/or HIF-2α have not
been identiﬁed as direct regulators of EPOR gene expression and
mechanisms underlying increased EPOR expression remain unknown.
Interestingly, in our study, the expression of EPOR was found to be di-
rectly upregulated by EPO in Schwann cells, macrophages and Jurkat
cells in vitro. In addition, EPO was reported to induce EPOR as well,
suggesting that EPO is not only an agonist of EPOR activation but
also an inducer of EPOR expression [33–35]. So, the increased EPOR
in peripheral nerves of EAN might be indirectly induced by HIF
through EPO induction. Further, the increased EPOR expression poten-
tially may increase the sensitivity of the expressing cells to available
EPO. Therefore, we hypothesize that the EPO activity in peripheral
nerves of EAN is a consequence of both an increase in EPO availability
in the local microenvironment and the induction of EPOR by EPO.
In EAN, as a result of HIF accumulation, HIF targeted genes, such as
EPO, were induced, but the contribution of EPO/EPOR pathway to EAN
progression remains unknown. It is known that EPOhas neuroprotective
effect and the application of EPO in several subtypes of neuropathy has
been investigated. EPO prevented the neurotoxic peripheral neuropathy
induced by chemotherapy agents such as docetaxel [36], cisplatin [37]
and paclitaxel [38], by sparing the number of normal nerve ﬁbers and
protecting the amplitude and area of compoundmuscle action potential.
For diabetic autonomic neuropathy, EPO therapy can prevent and even
partially reverse diabetic neuropathy by decreasing neuritic dystrophy
[39]. In addition, EPO also enhanced nerve regeneration and promoted
functional recovery in peripheral nerve injury and traumatic optic neu-
ropathy by reducing inﬂammation, and enhancing Schwann cell and
dorsal root ganglion neuron survival [40,41]. In HIV-associated sensory
neuropathy (HIV-SN), EPO prevented sensory axonal degeneration and
in vitro dorsal root ganglion neuron death, suggesting that EPO may be
useful in the treatment of HIV-SN [42]. For immune-neuropathy, the
up-expression of EPO in EAN was reported [43,44]. Thus far, two thera-
peutic treatments of EANwith exogenous EPOwere reported. Mausberg
et al. found that exogenous EPO could ameliorate EAN that shares fea-
tures of demyelinatin-form GBS by inducing TGF-β in macrophages
and Zhang et al. reported that exogenous EPO could enhance axon
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[43,45,46]. Our investigation here proved for the ﬁrst time that the deac-
tivation of HIF-induced EPO/EPOR pathway exacerbated EAN progres-
sion, indicating an endogenous protective effect of EPO/EPOR in
immune-neuropathy. However, it is clear that endogenous EPO is insuf-
ﬁcient to protect peripheral nerves from autoimmune injury, since
our data also showed that therapeutic treatment with exogenous EPO
greatly suppressed EAN propagation.
EPO promotes recovery of EAN, but the underlying mechanisms
remain unclear. EAN is an autoimmune inﬂammatory demyelinating
disorder, and Schwann cells, T cells and macrophages are the major
inﬂammatory and effector cells in EAN, which are essential for the de-
velopment and recovery of EAN. Schwann cells, macrophages and T
cells were reported to express EPOR, which was in agreement with
our ﬁndings here. Further our results here also clearly showed that
EPO could directly inﬂuence Schwann cell, macrophage and T cell
functions to promote EAN recovery.
Inﬂammation-mediated demyelination is the pathogenetic basis
of EAN and therefore Schwann cell protection and promotion of my-
elin formation are essential to EAN recovery. It was reported that
upon peripheral nerve injury, EPO and EPOR were induced on
Schwann cells, which promoted Schwann cell proliferation to protect
injured peripheral nerves and promote regeneration through an auto-
crine signalling pathway [47,48]. In line with this, we observed that
EPO and EPOR were induced in peripheral nerves in EAN and EPO
dose-dependently increased Schwann cell proliferation and de-
creased Schwann cell apoptosis in vitro. More interestingly, EPO
was ﬁrst found to induce synthesis of myelin associated protein by
Schwann cells through JAK2 related signal pathways. Therefore, in
EAN, EPO has cyto-protective effects on Schwann cell, which are im-
portant for the remyelination of the injured nerves.
T helper (Th) cells are important for the pathogenesis of EAN [4]. Th
cell polarization and proliferation following auto-antigen stimulation isFig. 7. Schematic diagram of EPO/EPOR mediated intrinsic protective pathway in EAN. Based o
then upregulates EPO and EPOR in EAN. The induced endogenous EPO/EPOR together with exog
inﬂammation activation to promote remyelination and decrease inﬂammation; inhibit T lymph
mation; and attenuate macrophage inﬂammatory activation but increase its phagocytic abilityessential for the determination of type and severity of autoimmune dis-
orders. In EAN, EPO and EPOR were induced in lymph nodes and EPO
signiﬁcantly suppressed lymphocyte proliferation, which may at least
partly contribute to the reduced T cell numbers in spleen and peripheral
nerves and therefore disease severity in EAN rats. Furthermore, in EAN,
EPO inhibited Th1 and Th17 polarization and promote Th2 and Treg dif-
ferentiation. EAN is considered to be mainly mediated by Th1 cells and
Th1 cytokines, such as IFN-γ or TNF-α [4]. In addition, Th17 cells were
believed to contribute to the development of EAN and GBS as well
[49]. Th2 cells thatmay suppress cell-mediated immunity and regulato-
ry T cells that can suppress the activation of the immune system may
contribute to the resolution of EAN [50]. Therefore, EPO signal can also
alter Th differentiation to favor EAN recovery.
Macrophages play dual roles in EAN, being detrimental in
attacking nervous tissue but also salutary, when aiding in the termi-
nation of the inﬂammatory process and the promotion of recovery
[16]. Interestingly, we found that numbers of macrophages were de-
creased during the initiation and propagation phases but increased
during the recovery phase of EAN by EPO treatment. In addition,
EPO suppressed the inﬂammatory activation of macrophages and in-
creased the phagocytic ability of macrophages which could be impor-
tant in the removing of apoptotic cells during the recovery stage of
EAN. So, EPO can suppress the cytotoxic effects and facilitate the pro-
tective effect of macrophages to promote EAN recovery.
Our investigation here supported the neuroprotective and immu-
nomodulatory effects of EPO in the demyelinatin-form EAN but which
effect is more important in EPO-promoted EAN recovery is unclear.
Our model system used here is inﬂammatory driven and inadequate
to be used as a model for neurodegeneration investigation, indicating
that the immunomodulatory activity of EPO may be the major con-
tributor for EPO-promoted EAN recovery in current experimental set-
ting. However, limited by our current data such hypothesis remains
elusive and needs further investigation.n our data, we hypothesize that autoimmune inﬂammation induces hypoxia and HIF that
enous EPO can: promote Schwann cell survival andmyelination production but inhibit its
ocyte proliferation and favor the Th2 and regulatory T cell polarization to reduce inﬂam-
to decrease inﬂammation but promote debris removal, to promote EAN recovery.
1270 B. Luo et al. / Biochimica et Biophysica Acta 1832 (2013) 1260–1270In summary, we observed a hypoxia-induced upregulation of
HIF-α, which further induced the expression of EPO/EPOR in sciatic
nerves of EAN. Both endogenous and exogenous EPO contributed to
EAN recovery by attenuating inﬂammation and exerting direct cell
protection (Fig. 7). Furthermore, EPO could be a particularly attractive
candidate for clinical use, because it has already been used for years
to treat the anemia associated with renal failure and hematological
malignancy and is known to be safe and effective with few side
effects. Our data reveal that EPO is an HIF-induced endogenous
protective molecule in EAN and could be a potent candidate for the
treatment of autoimmune neuropathies.
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